Discussion Incretin hormones play a key role in regulation of mammalian metabolism through regulation of insulin secretion as well as by decreasing gastric emptying, food intake, body weight and increasing satiety
Controlled studies have reported changes in glucose-related biomarkers and metabolic signaling endpoints, which researchers use to investigate how combined receptor engagement may alter endocrine pathway activity in experimental systems [2][3][5]
Retatrutide vs Semaglutide vs Tirzepatide: Researchers working across the incretin compound class frequently need to distinguish between these compounds when designing experimental models
Tirzepatide (Zepbound): Produced approximately 20.9% average body weight reduction in its SURMOUNT-1 trial over 72 weeks
That dynamic shifted in 2024, when Wegovy gained an indication for reduced cardiovascular risk in March and Zepbound added an OSA indication in December
These results were unprecedented at the time and established tirzepatide as the most effective weight loss medication on the market
